An early work, presented in 1995 by Dentico and colleagues, evaluated the effect of 30-day administration of high doses of intravenous or intramuscular GSH on liver cytolysis indexes in patients with chronic steatosic liver disease ( A subsequent study of Irie and colleagues in 2016 showed that the use of oral glutathione, at a daily dosage of 300 milligrams per day, may prevent NASH progression from NAFLD ( The study by Honda et al., conducted in 2017, was an open-label, single-arm, multicentre pilot study that evaluated the therapeutic effect of oral glutathione administration (300 mg/day) in patients with NAFLD through the evolution of biochemical indices (ALT) and liver fat levels assessed by VCTE ( These preliminary studies suggest a potential therapeutic effect of oral administration of GSH in NAFLD
Any significant weight loss, whether that happens through dieting medication, or bariatric surgery, typically includes some lean mass reduction
Obesity care has become a key focus area for large pharmaceutical companies, and dosing convenience can be an important differentiator for both patients and prescribers
Give us a call to discuss when youd like us to come by for your customized IV treatment
36 KoprivaS.MugfordS
